The Oncologist,volume 23,issue 2  (02-2018)

Period of time： 2018年2期

Publisher： John Wiley & Sons Inc

Founded in： 1996

Total resources： 209

E-ISSN： 1549-490x|23|2

ISSN： 1083-7159

Subject： R73 Oncology

Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

The Oncologist,volume 23,issue 2

Menu

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

The Oncologist,volume 23,issue 2 , Vol. 23, Iss. 2, 2018-02 , pp. 139-142

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Trailblazing Precision Oncology for Rare Tumor Subtypes

The Oncologist,volume 23,issue 2 , Vol. 23, Iss. 2, 2018-02 , pp. 143-144

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Cognitive Computing to Guide Molecular‐Based Therapy Selection: Steps Forward amid Abundant Need

The Oncologist,volume 23,issue 2 , Vol. 23, Iss. 2, 2018-02 , pp. 145-146

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure

The Oncologist,volume 23,issue 2 , Vol. 23, Iss. 2, 2018-02 , pp. 147-149

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E

The Oncologist,volume 23,issue 2 , Vol. 23, Iss. 2, 2018-02 , pp. 150-154

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors

The Oncologist,volume 23,issue 2 , Vol. 23, Iss. 2, 2018-02 , pp. 155-e17

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

The Oncologist,volume 23,issue 2 , Vol. 23, Iss. 2, 2018-02 , pp. 157-e21

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

The Oncologist,volume 23,issue 2 , Vol. 23, Iss. 2, 2018-02 , pp. 159-170

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach

The Oncologist,volume 23,issue 2 , Vol. 23, Iss. 2, 2018-02 , pp. 171-178

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Enhancing Next‐Generation Sequencing‐Guided Cancer Care Through Cognitive Computing

The Oncologist,volume 23,issue 2 , Vol. 23, Iss. 2, 2018-02 , pp. 179-185

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Previous 1 2 3 Next Display item(s) per page Total 22 item(s)